Member Info for Fevertreeman

You are absolutely correct...all the news that Newland has delivered since FDA approval have been DOWN WAVES

And you and I know to our cost that the biggest bloody ramper is our CEO !!! Only when he delivers against his own financial forecasts will serious investors start to take him seriously. ....

Question for Board and management team:”Is Angle actually now just an academic research unit? “ like other investors, am absolutely fed up with a continued pattern of behaviour from Newland - announcing BAU non-price sensitive meetings, hyping minor commercial agreements, & signalling world class results on tiny cohorts. When does this stop, Andrew? When do you start to behave like a responsible CeO and deliver some meaningful commercial progress? This is just vapourware ; where is the commercial news you promised to back your tripling of revenue forecast for 2024 of £6m?

...citing irretrievable differences, and those pesky Africans, so that he can enjoy a guilt-free, gilt-edged retirement courtesy of the annuity stream that is Kefi , which has provided him with large yearly consultancy fees paid into his low tax/no tax Cyprus bolthole for, seemingly, forever. Thereafter, he can sunbathe contentedly, knowing that his sunlit years and future business class flights are covered thanks to legions of AIM punters who thought there was a pot of gold (no pun intended) at the bottom of a still-to-be-completed African mine

One spiv handcuffs another

SB: "very disturbed by the significant disparity between narrative, plan and outcome." That disparityhas been carrying on for years with Adams, who repeatedly has proved himself to be a total charlatan. In simple terms, KEfi has proven a great example of how fools and their money are easily parted. Many others here have rec ite4d the litany of broken promises ( and downright lies) that Adams has delivered over an extended period of time. Kefi is proving to be a brilliant annuity income for Adams what with his salary and Cyprus consultancy payments. I personally dont think he cares about his shares, as they are almost worthless as it stands. His favourite trick is to take the gold price forecast and extrapolate that into revenue terms, which only works of course if you actuaqlly have a built mine that is actually producing the stuff. Adams hasnt actually managed to get any wet signatures on any financing for TK that would enable KEFI to start the process of building. And as s/o pointed out a yesterday or day before, the comments about local resettlement program are a carbon copy of statements he has made going back to 2017

And the big question is: "Where did Newland pluck the fig of £6m from?". Sadly the answer appear out of bloody thin air....it really is no way to manage a listed company

A big realignment in shareholdings appears underway. The question remains who is selling down their holding? Only comfort today is that despite the price action sp is holding steady. Difficult for the management team who must be fed up with the constant shenanigans

I agree- Eisei RNS was Jan 2nd, which in my experience means that they'd expected it to be signed & announced much earlier so that it was an FY2023 deal. Strip that tiny deal out of the equation, and we see that Newland & Griffiths have delivered no new commercial income year to date. Where is this mysterious 6m of revenues to come from Newland? Why did you put that figurer into the public domain without providing a shred of accompanying explanation or any mention of deal pipeline? and why did the Board allow you to say such a thing? I find it utterly incomprehensible that the Board, & the Nomad permit Newland to consistently mislead, obfuscate, & make the company hostage to fortune by consistently 'hyping' . His track record in doing so is destroying AGL's market credibility. Hard to find any one bar EC who believes that Newland needs a big cash injection. Problem is that as he is become persona non grata for big investors the level of trust toward him and Griffiths is at rock bottom, so highly likely that any cash raise will struggle.

Multiple issues here (1) FCA + Martin 'Look at Me/Alternative Regulator' Lewis campaign (2) FCA unquantifiable liability (3) Winterflood trading exposure to small cap - a market that is being crucified by lack of UK institutional support (4) Cancellation of 2024 Dividend +uncertainty over 2025 and beyond knocks away a key prop for sp as no income fund will buy if income so uncertain.....

Pretty much nailed it. Pinocchio Adams is shameless.

And now at 1pm its up to 1.7m shares ......and not a directors purchase in sight...but then why catch a falling knife.

The Board has been a disastrous steward of this company, allowing Newland and Griffiths to consistently 'hype' performance, mislead on prospects, alienate institutional holers, and offer no evidence for financial forecasts that appear to be plucked from the ether - Newland has told us that revenues will 3x this current financial year, but given no justification as to why he is confident, no pipeline comments, nothing that a reasonable investor can take a view on. The 'hype n hope' approach from the blustering Newland isn't a business strategy. So far the only commercial announcement so far has been the Eisei pilot study for 250k right at start of period, which presumably was a holdover from '23, so not a new shiny '24 deal. Selvey, former 18 years as chairman, arguably was the architect of the dismal lack of proper oversight, but it seems the current lot are no better at reining in the nonsense.

Another 1m+ traded already this morning. The institution is still selling down. The big question is who is it?

Newland got to be up there for worst CEO in AIM.....god knows there's a big enough choice

Missed the presentation, but had a quick shufti through the slides. HAving not heard the presentation, I'm unsure how to read Milverton's claim that SPA has sufficient cash (£1.1m) and facilities to cover working capital requirements and planned investment. Share price has reacted to Milverton and the FDs modest purchases after hrs last might and this morning.

Despite announcing the power division sale, which will improve the balance sheet, and confirming 2023 trading in line with market expectations, share price continues to head south. The lack of liquidity in the SME space is a big issue in the UK, and with so little institutional support, the gap between fundamental valuation and share price continues to make UK plc the bargain basement for corporate/PE shoppers. It would appear that what we have here with s/o determined to reduce/sell out their holding....over 1m traded today. Patience needed

So on Nov 9th, 4 months ago, Newland highlighted the following

- Revenue recognised for 2023 expected to be up 120% at c. £2.2m with sales secured in 2023 expected to be c. £3.3m

- Revenue recognised for 2024 expected to treble compared to 2023

- Cash runway extended into Q2 2025

Newland "The build-up of revenues has been slower than hoped but is moving in the right direction and the Company expects strong revenue growth year-on-year. The cost savings from the streamlining of our clinical services business will now extend the forecast cash runway into Q2 2025 and we look forward to progressing the planned launches of new products and services to drive widespread adoption of the Company's Parsortix system to support precision medicine in cancer."

Equally Newland can continue to drive this into the ground. Track record is there for all to see: he has completely alienated institutional shareholders; misled on timelines and news flow; produced no meaningful commercial contracts; and continually hyped statements to juice sp to drag in US punters. And along the way he managed to lose his main conduit to the US investor community Jefferies.

Because for $250,000 they have nothing to lose. They havent made any commitment beyond one pilot study. Newland of course positioned this completely differently, trailing some huge deal with a major international pharma...its one bloody pilot study Andrew!